Gelonghui, January 2 | Mailand (688273.SH) Investor Relations Activity Record Form shows that the company's hospital customers include level-III hospitals, level-II hospitals, first-level and community clinics, primary hospitals, etc. According to the company's 2023 semi-annual report data, the company's products have been used in about 7,400 hospitals across the country, including 4,100 level-II and above hospitals and 1,200 level-III hospitals. In 2023, the company's reproductive anti-aging series products are currently sold in some medical and aesthetic institutions.

In the future, the company will continue to focus on the iteration and expansion of technology and products in medical application scenarios, and continue to successfully replicate overall solutions into comprehensive healthcare markets such as public healthcare and private healthcare